To Summarise:
What do I do?
Step one: You NEVER know when somatostatin is going to act, Again since you don’t know if somatostatin is around you are rolling the dice by injecting GHRH. There will be zero GH release if somatostatin is around and only some if somatostatin is just starting up or just diminishing. Only if you are lucky to inject when somatostatin is gone will there be decent GH release. To overcome this, very large amounts say 2mg (2000mcg) are sometimes used.

Step two: Choose a GHRP because it can always cause GH release on its own and make the environment safe for GHRH.

Step three: Choose a GHRH to add to the GHRP because it will synergistic amplify the GH pulse.

Step four: Choose a dosing schedule. If once a day do it pre-bed. If twice a day then do it pre-bed and post workout (PWO). If three times a day do it pre-bed, PWO and in the morning.
How many times can I dose before I lose pulsation? Six (6) a day every 3 hours, How few times can I do it for some better sleep, small anti-aging effect? Just pre-bed.

Step five: Assess tolerance by dosing just once w/ a GHRP pre-bed at half of saturation dose. Then if that goes well go to full saturation dose. If that goes well add a 2nd dosing, If that is fine add a third dosing.

Step six: Decide on a dose. Saturation dose is defined as either 100mcg or 1mcg/kg of bodyweight in the studies. For the most part it is treated as 100mcg. That is the same for women and men. You will get added but diminishing benefit by dosing 200mcg, 300mcg perhaps 400mcg.

BOOM Dosing:

Another popular method to using these Peptides is to use a BOOM dose of Ipamorelin (2mg +) before bed time, this creates the original pulse of GH along with several smaller ones through the night. This really can only be carried out with Ipamorelin as there is no issues with Prolactin or Cortisol increase.

the protocol would be to use a larger amount of the GHRP peptide Ipamorelin lets say at 2mg – 5mg along with the standard dose of 100mcg of Mod GRF before you retire to bed (the same rules apply about food and timings) any less and you are not BOOM dosing
“

P-11 IPAMORELIN – A NOVEL VERY POTENT GROWTH HORMONE SECRETAGOGUE
MH Rasmussen, B Soogaar, L YnddaI, L Groes, L Helmgaard, L Nordholm. Novo Nordisk A/S, Clinical Development, Bagsvaerd, Denmark.
”
this study above shows that at high dose Ipamorelin continues to remain active for 5 to 6 hours, this means dose of 4mgs will result in Ipamorelin in plasma exerting an effect for more than 5 hours…

I have trailed this method using 2mg – 4mg of IPAM along with 100mcg of Mod GRF and it has enhanced my sleep dramatically, plus the improvement in my condition was better than i expected.

certainly something worth considering to add to the standard 3-5 x day saturation dosing schedule many follow.

Using CJC1295 DAC for a raising your basel GH & IGF-1 levels

there is new data to show the potential usefulness of the peptide CJC1295 DAC, recent studies have shown a 7.5 fold increase in basel GH levels and a 1-3fold increase in IGF-1 levels when using doses of 30-60mcg per kg, so for a 100kg person this would be 3-6mg per week……

Here we have two studies from the Journal of Endocrinology and Metabolism which show some documented dosage and specific details on how CJC-1295 induces GH elevations. These are only abstracts and are pretty simple in what they say. Regardless, this is a good starting point for understanding how our new friend CJ does his job, and a point from which more in-depth discussion can begin.

As you can see, CJC-1295 creates a prolonged stimulation of GH without eliminating the pulsatile release of GH. It does however increase the basal levels (trough) of GH in the body by 7.5 fold, as seen in the second study.

Dosages used ranged from 30-60 mcg/kg in the first study and 60-90 mcg/kg in the second study. These dosages did not have any apparent, serious side effects, and could be considered relatively safe for short term usage. For affordability’s sake, we will have to see whether or not dosages like these are realistic for the average user. Granted, this analog of GHRH would be dosed much less frequently than the peptides we are used to using, and for that matter, the price difference could be minimal, or even in our favor! Not to mention, less injections is probably favored by most – if not all

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.


CONTEXT:
Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.

OBJECTIVE:
The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.

DESIGN:
The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.

SETTING:
The study was performed at two investigational sites.

PARTICIPANTS:
Healthy subjects, ages 21-61 yr, were studied.

INTERVENTIONS:
CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.

MAIN OUTCOME MEASURES:
The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.

RESULTS:
After a single injection of CJC-1295, there were dose-dependentincreases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC-1295 was 5.8-8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.

CONCLUSIONS:
Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.






J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. Epub 2005 Dec 13.

--------------------------------------------------------------------------------



Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.



CONTEXT:
Pulsatile GH secretion is considered important for many of the hormone’s physiological effects. Short-term GHRH infusions enhance GH pulsatility and increase IGF-I, but the short GHRH half-life limits its therapeutic use. A synthetic GHRH analog (CJC-1295) that binds permanently to endogenous albumin after injection (half-life = 8 d) stimulates GH and IGF-I secretion in several animal species and in normal human subjects and enhances growth in rats.

OBJECTIVE:
Our objective was to assess GH pulsatility after a single injection of CJC-1295 and determine which GH secretion parameters correlated to the increase in IGF-I production.

METHODS:
GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.

RESULTS:
GH secretion was increased after CJC-1295 administration with preserved pulsatility. The frequency and magnitude of GH secretory pulses were unaltered. However, basal (trough) GH levels were markedly increased (7.5-fold; P < 0.0001) and contributed to an overall increase in GH secretion (mean GH levels, 46%; P < 0.01) and IGF-I levels (45%; P < 0.001). No significant differences were observed between the responses to the two drug doses. The IGF-I increases did not correlate with any parameters of GH secretion.

CONCLUSIONS:
CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory capability.







J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. Epub 2006 Oct 3.



So in basic terms the use of higher dose CJC1295 (GHRH) will raise basel and IGF-1 levels




“

CJC-1295 Decay Rate Chart

A single dose of CJC-1295 “decays” by about 10% a day. So that single dose will follow the “effectiveness” percentages indicated below over the week:
_______Dose (2mg)
Day 0 – 100% (2mg)
Day 1 – 90% (1.8mg remaining)
Day 2 – 81% (1.6mg remaing)
Day 3 – 73% (1.4mg remaining
Day 4 – 65% (1.3mg remaining)
Day 5 – 59% (1.1mg remaining)
Day 6 – 53% (1mg remaining)
Day 7 – 47% (.9mg remaining)
Day 8 – 43% (.8mg remaining)

So a once a week dosing protocol would result in less consistent GH blood levels then the twice a week dosing indicated below (especially so after the initial buildup):

______Dose #1_(1mg)__________Dose #2_(1mg)__________Dose #3_(1mg)
Day 0 – 100% (1mg)
Day 1 – 90% (.9mg remaining)
Day 2 – 81% (.8mg remaing)
Day 3 – 73% (.7mg remaining)
Day 4 – 65% (.6mg remaining) + 100% (1mg) = 1.6mg
Day 5 – 59% (.5mg remaining) + 90% (.9mg remaining) = 1.4mg
Day 6 – 53% (.5mg remaining) + 81% (.8mg remaing) = 1.3mg
Day 7 – 47% (.4mg remaining) + 73% (.7mg remaining) = 1.1mg
Day 8 – 43% (.3mg remaining) + 65% (.6mg remaining) + 100% (1mg) = 1.9m

Thanks for the post. I actually read the exact same article while researching ghrp 2. Seems a lot of other posts elsewhere more or less repeat all the above.

Great read thanks